First FDA Approved Subcutaneous Implantable Defibrillator Available for Patients at Risk for Sudden Cardiac Arrest
“The S-ICD system provides physicians with a new treatment option for patients who are at risk of sudden cardiac arrest,” said Bradley Knight, MD, electrophysiologist and medical director of the Center for Heart Rhythm Disorders. “The system sits entirely below the skin without requiring the need for placing wires in the heart, which leaves the heart and blood vessels untouched.”
The Boston Scientific S-ICD® System has two main components. One is called the pulse generator, which powers the system, monitors heart activity and delivers a shock if needed. The other main component is the electrode. This enables the device to sense the heart rhythm and deliver shocks when necessary. Both are implanted just under the skin, providing protection without touching the heart and reliable defibrillation without transvenous wires.
“Patients who previously could not undergo the implantation of a transvenous defibrillator, now have a device option to protect them from deadly arrhythmias,” said Dr. Knight.
The S-ICD system is commercially available in many countries in Europe as well as New Zealand. More than 1,400 devices have been implanted in patients around the world.
For more information about the subcutaneous implantable defibrillator and other services at the Bluhm Cardiovascular Institute, or to schedule an appointment, please call 312.926.0779.